Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age
Clinical trial NCT04520659 · COMPLETED
Trial details
- NCT number
- NCT04520659
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-16
- Primary completion
- 2024-04-18
- Enrollment
- 81
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.